Vote Scores
Filings read through

ARS Pharmaceuticals, Inc.: how funds voted at the meeting of 24 Jun 2026

Ticker
SPRY
Meeting
Season
year to 30 June 2026
Filers reporting
309
Ballot items
4

309 filers on Form N-PX reported votes at the ARS Pharmaceuticals, Inc. meeting of 24 Jun 2026. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    3 nominees. 51.3% of the reported votes are for. 65 filers withheld from or voted against at least one nominee.

    426 vote records from 82 filers. 43 of the 78 filers that marked the item voted against management. 4 filers gave no management mark.

    • Positions of 33 fund families
    • For 12
    • Abstain or withhold 20
    • Split or no vote 1
    • Against management 19
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    434 vote records from 307 filers. 129 of the 289 filers that marked the item voted against management. 18 filers gave no management mark.

    • Positions of 40 fund families
    • For 19
    • Against 20
    • Split or no vote 1
    • Against management 19
  3. Item 3: Frequency of the say-on-pay vote

    One year: 275 filers. Three years: 7 filers. For: 6 filers. Not applicable: 2 filers. Abstain: 1 filer. 1-year: 1 filer.

    425 vote records from 306 filers. 7 of the 288 filers that marked the item voted against management. 18 filers gave no management mark.

    • Positions of 40 fund families
    • For 1
    • Split or no vote 39
    • Against management 1
  4. Item 4: Audit-related items (auditor ratification)

    142 vote records from 82 filers. 0 of the 78 filers that marked the item voted against management. 4 filers gave no management mark.

    • Positions of 33 fund families
    • For 32
    • Split or no vote 1

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at ARS Pharmaceuticals, Inc., meeting of 24 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Pay-vote frequency4. Auditor
AllianceBernsteinAgainst, against managementSplitNo report
AllspringAgainst, against managementSplitFor
American CenturyAgainst, against managementSplitFor
BairdAgainst, against managementSplitNo report
BlackRock and iSharesForSplitFor
BNY MellonForSplitNo report
Brighthouse FundsAgainstForFor
Charles SchwabForSplitFor
Columbia ThreadneedleAgainst, against managementSplitFor
DimensionalAgainst, against managementSplit, against managementFor
DWSAgainst, against managementSplitFor
EquitableAgainst, against managementSplitFor
FidelityForSplitFor
First TrustAgainst, against managementSplitNo report
Franklin TempletonAgainst, against managementSplitFor
Global XForSplitFor
Goldman SachsForSplitFor
Guggenheim and RydexAgainst, against managementSplitFor
InvescoAgainst, against managementSplitFor
J.P. MorganForSplitFor
Jackson National fundsSplitSplitSplit
John Hancock and ManulifeAgainst, against managementSplitFor
Lincoln FinancialForSplitFor
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementSplitFor
NationwideForSplitFor
Natixis and Loomis SaylesForSplitNo report
Neuberger BermanForSplitNo report
Northern Trust and FlexSharesAgainst, against managementSplitFor
Nuveen and TIAAForSplitFor
Pacific Life fundsForSplitFor
PGIM and PrudentialForSplitFor
PrincipalAgainst, against managementSplitFor
ProShares and ProFundsAgainst, against managementSplitFor
Russell InvestmentsForSplitNo report
SEIForSplitFor
State Street and SPDRForSplitFor
T. Rowe PriceAgainst, against managementSplitFor
VanguardForSplitFor
Victory CapitalAgainst, against managementSplitFor
VoyaForSplitFor

Questions

How many filers reported votes at the ARS Pharmaceuticals, Inc. meeting?
309 Form N-PX filers reported votes at the meeting of 24 Jun 2026. On say-on-pay, 129 of 289 filers that marked the item voted against management (44.6%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. ARS Pharmaceuticals, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list ARS Pharmaceuticals, Inc. with a meeting date within three days of 24 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .